Amgen As Model For Corporate Governance: CEO Says Ignorance Is No Excuse
CEOs should not be permitted to argue that they are ignorant of ethical deviations within their companies, Amgen CEO Kevin Sharer declared Jan. 14 during the J.P. Morgan health care conference in San Francisco
You may also be interested in...
Ex-Pharmacia exec Michael DuBois will head Schering-Plough's newly formed product licensing division
ImClone expects to resubmit the BLA for Erbitux (cetuximab) during the first quarter after addressing the issues raised in FDA's "refuse-to-file" letter for the colorectal cancer treatment
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011